On September 6^th, 2024, representatives from Celltrion, a Korean biopharmaceutical company, visited the Shanghai Operations Management Center of Hasten Biopharmaceutical Co.,Ltd  (referred to as “Hasten”). After the official announcement of acquisition for 14 branded drugs’ commercial rights from Celltrion in multiple Asia-Pacific countries and regions on June 28th, two parties conducted thorough discussions on the latest progress of the transition.

To acknowledge the project members of both parties for their unremitting efforts during the transaction, Hasten invited Celltrion delegation and project team members to jointly celebrate on the achievement of this milestone. During the ceremony, Celltrion representative handed over to Hasten the “key of success” symbolizing that two companies’ shared vision of providing healthcare solutions for patients will be continued. Leaders from two parties also toasted for the milestone and win-win result.

Summer XIA, CEO of Hasten, said, “it is our honor to be able to reunite with Celltrion in Hasten Shanghai Office. With this transaction, Hasten will fully accelerate the commercialization in the Pan-Asia region and further expand the international market, so as to bring more high-quality products and solutions to patients in the Asia-Pacific region and even around the world and create social value.”

CEO of Celltrion APAC, Ho Seung Shin said: “Congratulations to the Hasten team for successfully concluding this significant strategic cooperation and accelerating the commercialization of the Asia-Pacific region. It is believed that with Hasten's innovative business mode and strong commercial capabilities, the value and potential of these 14 branded products will be fully explored and unleashed and continually benefiting more patients.”

Hasten SVP, Head of Commercial Excellence, Hanson ZHENG said:“Special thanks to each member of the teams on both sides for their tireless efforts and contributions in making this transaction possible. This acquisition is not only a major breakthrough in the Hasten's business development, but also a big step for Hasten to achieve the strategic goal of 'whole industry chain' and 'globalization'.”

Hasten VP, the Head of Asia-Pacific, Peggy FUNG said, “Hasten has always adhered to the principle of ‘rooted in China, thinking globally’. Relying on the existing long-term and stable Asia-Pacific business foundation built by the Celltrion team, Hasten will be able to make smooth transition and embrace rapid development soon. By synergizing the resources and advantages, we’ll expand to other markets and widen  our business boundaries globally.”

For the past months, Hasten and Celltrion have worked closely together to explore an innovative path for biopharmaceuticals to go overseas; looking forward, both companies will promote the prosperity of the healthcare industry under the guidance of their visions and missions respectively, benefiting to the patients around the globe and jointly safeguard the health and well-being of mankind.